Dissolvable polymer microneedles for drug delivery and diagnostics.

Dissolvable transdermal microneedles (µND) are promising micro-devices used to transport a wide selection of active compounds into the skin. To provide an effective therapeutic outcome, µNDs must pierce the human stratum corneum (~10 to 20 µm), without rupturing or bending during penetration, then release their cargo at the predetermined area and time. The ability of dissolvable µND arrays/patches to sufficiently pierce the skin is a crucial requirement, which depends on the material composition, µND geometry and fabrication techniques. This comprehensive review not only provides contemporary knowledge on the µND design approaches, but also the materials science facilitating these delivery systems and the opportunities these advanced materials can provide to enhance clinical outcomes.

Polymer-based microneedle composites for enhanced non-transdermal drug delivery

The applications of microneedles (MNs) are becoming popular with the promise of efficient and advanced drug delivery. MNs were developed to overcome the limitations of conventional drug delivery systems and bypass biological barriers. While most MN applications in the past decades focused on transdermal biomedical appli-cations, recent advancements in engineering and technology have enabled MNs to be used in a wide range of non-transdermal applications. Compared with the other types of MNs, polymer-based MN composites have attracted more attention for non-transdermal drug delivery because they exhibit excellent biological properties, including being nontoxic, biocompatible, and biodegradable, making them ideal biomaterials for drug delivery applications that overcome the metabolic constraints of drug delivery for macromolecular payloads across a variety of tissues and organs other than the skin. This review provides an overview of recent advancements in polymer-based MN composite carriers that aim to overcome the delivery challenges for non-transdermal drug delivery, specifically in the vascular, ocular, gastrointestinal tract, buccal transmucosal, periodontal, cardio-vascular, and vaginal tissue. Furthermore, this review will discuss future perspectives and challenges for poly-meric MN composites in non-transdermal drug delivery that must be resolved.

Dissolving microneedle patches loaded with amphotericin B microparticles for localised and sustained intradermal delivery: Potential for enhanced treatment of cutaneous fungal infections.

Fungal infections affect millions of people globally and are often unreceptive to conventional topical or oral preparations because of low drug bioavailability at the infection site, lack of sustained therapeutic effect, and the development of drug resistance. Amphotericin B (AmB) is one of the most potent antifungal agents. It is increasingly important since fungal co-infections associated with COVID-19 are frequently reported. AmB is only administered via injections (IV) and restricted to life-threatening infections due to its nephrotoxicity and administration-related side effects. In this work, we introduce, for the first time, dissolving microneedle patches (DMP) loaded with micronised particles of AmB to achieve localised and long-acting intradermal delivery of AmB for treatment of cutaneous fungal infections. AmB was pulverised with poly (vinyl alcohol) and poly (vinyl pyrrolidone) to form micronised particles-loaded gels, which were then cast into DMP moulds to form the tips. The mean particle size of AmB in AmB DMP tips after pulverisation was 1.67 ± 0.01 µm. This is an easy way to fabricate and load microparticles into DMP, as few steps are required, and no organic solvents are needed. AmB had no covalent chemical interaction with the excipients, but the crystallinity of AmB was reduced in the tips. AmB was completely released from the tips within 4 days in vitro. AmB DMP presented inhibition of Candida albicans (CA) and the killing rate of AmB DMP against CA biofilm inside porcine skin reached 100% within 24 h. AmB DMP were able to pierce excised neonatal porcine skin at an insertion depth of 301.34 ± 46.86 µm. Ex vivo dermatokinetic and drug deposition studies showed that AmB was mainly deposited in the dermis. An in vivo dermatokinetic study revealed that the area under curve (AUC0-inf) values of AmB DMP and IV (Fungizone® bolus injection 1 mg/kg) groups were 8823.0 d∙µg/g and 33.4 d∙µg/g, respectively (264-fold higher). AmB remained at high levels (219.07 ± 102.81 µg/g or more) in the skin until 7 days after the application of AmB DMP. Pharmacokinetic and biodistribution studies showed that AmB concentration in plasma, kidney, liver, and spleen in the AmB DMP group was significantly lower than that in the IV group. Accordingly, this system addressed the systemic side effects of intravenous injection of AmB and localised the drug inside the skin for a week. This work establishes a novel, easy and effective method for long-acting and localised intradermal drug delivery.